NFE2L2 Mutation

CI-VAR-00002706Explore in graph →CIViC 2749

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
NFE2L2 Mutation OR KEAP1 Mutation OR CUL3 Mutation	Platinum Doublet	Predictive	B	Supports Resistance	2	accepted	EID12558 In a retrospective study of stage IV NSCLC patients treated with first-line platinum doublet chemotherapy (n = 103; 51 KEAP1/NFE2L2/CUL3-mutant, 52 WT), mutations in NFE2L2, KEAP1, or CUL3 were associ… (full text at CIViC) PMID 31548347 · Jeong et al., 2020 · Open in CIViC	civic
Lung Squamous Cell Carcinoma2
NFE2L2 Mutation	Sapanisertib	Predictive	B	Supports Sensitivity Response	3	submitted	EID7425 In a phase 2 trial, patients with squamous cell lung carcinoma harboring NFE2L2 mutation were treated with oral TORC1/2 inhibitor TAK228. ORR 25% (1 PR, 3 SD, 0 PD). Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Squamous Cell Carcinoma1
NFE2L2 Mutation	(oncogenic)	Oncogenic	B	Supports Oncogenicity	3	submitted	EID12559 In a mutational analysis of 1,145 primary cancers, NFE2L2 (NRF2) mutations occurred predominantly in squamous cell carcinomas (SCCs) of the esophagus (11.4%), skin (6.3%), lung (15.8%), and larynx (13… (full text at CIViC) PMID 19967722 · Kim et al., 2010 · Open in CIViC	civic